medigraphic.com

1998, Número 1

<< Anterior Siguiente >>

Vet Mex 1998; 29 (1)


Bases farmacológicas del uso de antiinflamatorios no esteroidales en caballos

Lizárraga MI, Sumano LH

Idioma: Español/Inglés
Referencias bibliográficas: 107
Paginas: 83-99
Archivo PDF: 1464.67 Kb.


RESUMEN

El uso de antiinflamatorios no esteroidales en la clínica de equinos es una práctica común. En este ensayo se resume la información clínico-farmacológica más relevante en cuanto al uso de estos fármacos. En este sentido, los datos vertidos no resultan de la extrapolación en otras especies. Se pretende que la información compilada permita dar un uso más racional a dichos medicamentos, estrechando la brecha que se genera entre el clínico sujeto a una enorme carga de trabajo y la información creciente sobre el particular. Se destacan únicamente aspectos básicos de la fisiopatología de la inflamación y se hace mención de los antiinflamatorios no esteroidales más utilizados en equinos; por ejemplo, fenilbutazona, flunixina meglumina, así como de los que se encuentran en fase experimental en esta especie (piroxicam, eltanaco, ácido tolfenámico). A pesar de su baja toxicidad, se destacan los signos clínicos y hallazgos de necropsia generados por el mal uso de aquellos fármacos y con base en sus rasgos farmacocinéticos y farmacodinámicos se presentan las dosis y los usos de los medicamentos aceptados por la comunidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Boothe DM. The analgesic-antipyretic-antiinflammatory drugs. In: Adams HR, editor. Veterinary pharmacology and therapeutics. 7th ed. Ames (IO): Iowa State University Press, 1995:432-449.

  2. Lees P, May SA. Inflammation and anti-inflammatory drugs. In: Andrews AH, Blowey RW, Boyd H, Eddy RG, editors. Bovine medicine. Diseases and husbandry of cattle. Oxford (UK): Blackwell Scientific Publications, 1992:843-863.

  3. Pérez R. Bases biológicas de la inflamación. En: Katona G, editor. Inflamación y antiinflamatorios. Actualizaciones. México (DF): Instituto Syntex, 1981:9-14.

  4. Snow DH. Agentes antiinflamatorios. En: Bogan JA, Lees P, Yoxall AT, editores. Bases farmacológicas de la medicina en grandes especies. México (DF): Científica, 1986:371-404.

  5. Willoughby DA, Koh MS, Parente L. Inflamación inmunológica y no inmunológica. La inflamación pleural como modelo. En: Katona G, editor. Inflamación y antiinflamatorios. Actualizaciones. México (DF): Instituto Syntex, 1981:15-23.

  6. Roelvink MEJ, Goossens L, Kalsbeek HC, Wensing T. Analgesic and spasmolytic effects of dipyrirone, hyoscine-N-butylbromide anda combination of the two in ponies. Vet Rec 1991;129:378-380.

  7. Kallings P. Nonsteroidal anti-inflammatory drugs. Vet Clin North Am Equine Pract 1993;9:523-541.

  8. Landoni MF, Lees P. Comparison of the anti-inflammatory actions of flunixin and ketoprofen in horses applying PK/PD modelling. Equine Vet J 1995;27:247-256.

  9. MacAllister CG. Nonsteroidal anti-inflammatory drugs: Their mechanism of action and clinical uses in horses. Vet Med 1994;89:237-240.

  10. Barragry TB. Veterinary drugs therapy. Philadelphia (PA): Lea & Febiger, 1994.

  11. Prügner W, Huber R, Lühman R. Eltenac, a new anti-inflammatory and analgesic drug for horses: clinical aspects. J Vet Pharmacol Ther 1991;14:193-199.

  12. Lees P, McKellar Q, May SA, Ludwing B. Pharmacodynamics and pharmacokinetics of carprofen in the horse. Equine Vet J 1994;26:203-208.

  13. May SA. Anti-inflammatory agents. In: Robinson, NE, editor. Current therapy in equine medicine. 3rd ed. Philadelphia (PA): Saunders Co., 1992:14-18.

  14. Toutain P, Lassourd V, Costes G, Alvinerie M, Bret L, Lefebvre HP, et al. A non-invasive and quantitative method for the study of tissue injury caused by intramuscular injection of drugs in horses. J Vet Pharmacol Ther 1995;18:226-235.

  15. Galván JC. Usos terapéuticos y propiedades farmacológicas de la fenilbutazona en equinos. Estudio recapitulativo (tesis de licenciatura). México (DF) México: Facultad de Medicina Veterinaria y Zootecnia. UNAM, 1983.

  16. Tobin T, Chay S, Kamerling S, Woods WE, Weckman TJ, Blake JW, et al. Phenylbutazone in the horse: a review. J Vet Pharmacol Ther 1986;9:1-25.

  17. Plumb DC. Veterinary drug handbook. 2nd ed. Ames (IO): Iowa State University Press, 1995.

  18. Jaussaud P, Guieu D, Bellon C, Barbier B, L'Hopital MC, Sechet R, et al. Pharmacokinetics of tolfenamic acid in the horse. Equine Vet J 1992:24:(Suppl. II)69-72.

  19. Jaussaud P, Guieu D, Courtot D, Barbier B. Identification of a tolfenamic acid metabolite in the horse by gas chromatography-mass spectrometry. J Chromat Biomed Appl 1992;573:136-140.

  20. Lees P, Higgins AJ. Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse. Equine Vet J 1985;17:83-96.

  21. Holbrook TC, Moore JN. Anti-inflammatory and immune support in endotoxemia and septicemia. Vet Clin North Am Equine Pract 1994;10:535-547.

  22. Maitho TE, Lees P, Taylor JB. Absorption and pharmacokinetics of phenylbutazone in Welsh Mountain ponies. J Vet Pharmacol Ther 1986;9:26-39.

  23. Wilcke JR, Crisman MK, Sams RA, Gerken DF. Pharmacokinetics of phenylbutazone in neonatal foals. Am J Vet Res 1993;54:2064-2067.

  24. Piperno E, Ellis DJ, Getty SM, Brody TM. Plasma and urine levels of phenylbutazone in the horse. J Am Vet Med Assoc 1968;153:195-198.

  25. Landuyt J, Delbeke FT, Debackere M. The intramuscular bioavailability of a phenylbutazone preparation in the horse. J Vet Pharmacol Ther 1993;16:494-500.

  26. Soma LR, Behrend E, Rudy J, Sweeney RW. Disposition and excretion of flunixin meglumine in horses. Am J Vet Res 1988;49:1894-1898.

  27. Semrad SD, Sams RA, Ashcraft SM. Pharmacokinetics of and serum thromboxane suppresion by flunixin meglumine in healthy foals during the first month of life. Am J Vet Res 1993;54:2083-2087.

  28. Welsh JCM, Lees P, Stodulski G, Cambridge H, Foster AP. Influence of feeding schedule on the absorption of orally administered flunixin in the horse. Equine Vet J 1992;24:(Suppl II)62-65.

  29. Jensen RC, Fischer JH, Cwik MJ. Effect of age and training status on pharmacokinetics of flunixin meglumine in Thoroughbreds. Am J Vet Res 1990;51:591-594.

  30. Soma LR, Uboh CE, Rudy JA, Fegely J. Plasma concentrations of flunixin in the horse: its relationship to thromboxane B2 production. J Vet Pharmacol Ther 1992;15:292-300.

  31. Delbeke FT, Debackere M, Vynckier L. Disposition of human drug preparations in the horse. I. Rectally administered indomethacin. J Vet Pharmacol Ther 1991;14:145-149.

  32. Owens JG, Kamerling SG, Barker SA. Pharmacokinetics of ketoprofen in healthy horses and horses with acute synovitis. J Vet Pharmacol Ther 1995;18:187-195.

  33. Sams R, Gerken DF, Ashcraft SM. Pharmacokinetics of ketoprofen after multiple intravenous doses to mares. J Vet Pharmacol Ther 1995;18:108-116.

  34. Jaussaud P, Bellon C, BesseS, Courtot D, Delatour P. Enantioselective pharmacokinetics of ketoprofen in horses. J Vet Pharmacol Therap 1993;16:373-376.

  35. Landoni MF, Lees P. Influence of formulation on the pharmacokinetics and bioavailability of racemic ketoprofen in horses. J Vet Pharmacol Ther 1995;18:446-450.

  36. Benoit E, Jaussaud P, Besse S, Videmann B, Courtot D, Delatour P et al. Identification of a benzhydrolic metabolite of ketoprofen in horses by gas chromatography mass spectrometry and high performance liquid chromatography. J Chromat Biomed Appl 1992;583:167-173.

  37. Lees P, Sedgwick AD, Higgins AJ, Pugh KE, Bush U. Pharmacodynamics and pharmacokinetics of miloxicam in the horse. Br Vet J 1991;147:97-108.

  38. Soma LR, Uboh CE, Rudy JA, Perkowski SZ. Plasma and synovial fluid kinetics, disposition, and urinary excretion of naproxen in horses. Am J Vet Res 1995;56:1075-1080.

  39. Gerken DF, Sams RA. Pharmacokinetics of oxyfenbutazone in horses. J Vet Pharmacol Ther 1988;11:283-287.

  40. Jaussaud P, Courtot D. Caracteres analytiques, pharmacocinétiques et métaboliques du piroxicam application au controle antidopage chez le cheval. Revue Méd vét 1988;1399:35-40.

  41. Delbeke FT, Vynckier L, Debackere M. The disposition of suxibuzone in the horse. J Vet Pharmacol Ther 1993;16:283-290.

  42. Paradis MR. Equine respiratory viruses. In: Smith BP, editor. Large animal internal medicine. St. Louis (MO): The CV Mosby Co., 1990:524-529.

  43. Smith JA. Diseases of the pharynx, larynx, and trachea. In: Smith BP, editor. Large animal internal medicine. St. Louis (MO): The CV Mosby co., 1990:565-578.

  44. Wiske SE. The bronchopneumonias. In: Smith BP, editor. Large animal internal medicine. St. Louis (MO): The CV Mosby Co., 1990:582-594.

  45. Semrad SD, Sams RA, Harris ON, Ashcraft SM. Effects of concurrent administration of phenylbutazone and flunixin meglumine on pharmacokinetic variables and in vitro generation of thromboxane B2 in mares. Am J Vet Res 1993;54:1901-1905.

  46. Firth EC, Nouws JFM, Klein WR, Driessens F. The effect of phenylbutazone on the plasma disposition of penicillin G in the horse. J Vet Pharmacol Ther 1990;13:179-185.

  47. Burrows GE, MacAllister CG, Tripp P, Black J. Interactions between chloramphenicol, acepromazine, phenylbutazone, rifampin and thiamylal in the horse. Equine Vet J 1989;21:34-38.

  48. Araujo ACP, Salvadori MC, Velletri ME, Camargo MMA. Influence of furosemide on the detection of flunixin meglumine in horse urine samples. J Anal Toxic 1990;14:146-148.

  49. Stevenson AJ, Weber MP, Todi F, Mendonca M, Fenwick JD, Kwong E, et al. The influence of furosemide on plasma elimination and urinary excretion of drugs in standardbred horses. J Vet Pharmacol Ther 1990;13:93-104.

  50. Zertuche JML, Brown MP, Gronwall R, Merritt K. Effect of probenecid on the pharmacokinetics of flunixin meglumine and phenylbutazone in healthy mares. Am J Vet Res 1992;53:372-374.

  51. May SA, Hooke RE, Lees P. The effect of drugs used in the treatment of osteoarthrosis on stromelysin (proteoglycanase) of equine synovial cell origin. Equine Vet J 1988: 6(Suppl.):28-32.

  52. Auer DE, Ng JC, Reilly JS, Seawright AA. Anti inflammatory drugs inhibit degradation of equine synovial fluid induced by free radicals. Austr Vet J 1991;68:403-405.

  53. Jolly WT, Whittem T, Jolly AC, Firth EC. The dose-related effects of phenylbutazone and a methylprednisolone acetate formulation (Depo-Medrol) on cultured explants of equine carpal articular cartilage. J Vet Pharmacol Ther 1995;18:429-437.

  54. Auer DE, Ng JC, Seawright AA. Superoxide production by stimulated equine polymorphonuclear leukocytes inhibition by anti inflammatory drugs. J Vet Pharmacol Ther 1990;13:59-66.

  55. Keck G. Toxicité et effets indesirables des anti inflammatoires non steroidiens. Etude des cas rapportes au CNITV (Centre National d'Informations Toxicologiques Vétérinaires). Rec Méd Vét 1992;168:615-620.

  56. MacAllister CG, Taylor-MacAllister C. Treating and preventing the adverse effects of nonsteroidal anti-inflammatory drugs in horses. Vet Med 1994;89:241-246.

  57. MacAllister CG, Morgan SJ, Borne AT, Pollet AR. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc 1993;202:71-77.

  58. Murray MJ. Nonsteroidal antiinflammatory drugs toxicity. In: Smith BP, editor. Large animal internal medicine. St. Louis (MO): The CV Mosby Co., 1990:665-668.

  59. Traub-Dargatz JL. Non-steroidal anti-inflammatory druginduced ulcers. Proceedings of the 33rd Annual Convention of the American Association of Equine Practitioners; 1987 December 2; New Orleans (Louisiana) U.S.A. Lexington (Kentucky): American Association of Equine Practitioners, 1988:129-132.

  60. Samperio JC. Efectos de la administración crónica de dipirona sobre algunas constantes hematológicas en equinos (tesis de licenciatura). México (DF) México. Facultad de Medicina Veterinaria y Zootecnia. UNAM, 1985.

  61. Hunt JM, Lees P, Edwards GB. Suspected non-steroidal antiinflammatory drug toxicity in a horse. Vet Rec 1985;117:581-582.

  62. Longo F, Autefage A, Bayle R, Keister M, Van Gool F. Efficacy of a non steroidal anti inflammatory, ketogen 10% (ketoprofen) in the treatment of colic in horses. J Equine Vet Sci 1992;12:311-315.

  63. Allen D, Clark, ES, Murray MJ. Disorders of the small intestine. In: Smith BP, editor. Large animal internal medicine. St. Louis (MO): The CV Mosby Co., 1990:654-659.

  64. Allen DG, Pringle JK, Smith D, Conlon P, Burgmann PM. Handbook of veterinary drugs. Philadelphia (PA): JB Lippincott Co., 1993.

  65. Duran S, Ravis W. Comparative pharmacokinetics of H2 antagonists in horses. Proceedings of the Eleventh Annual Veterinary Medical Forum; 1993 May 22-25; Washington (DC) U.S.A. Lakewood (Colorado): American College of Veterinary Internal Medicine, 1993:687-690.

  66. Heath MF, Evans RJ, Poole AW, Hayes LJ, McEvoy RJ, Littler RM. The effects of aspirin and paracetamol on the aggregation of equine blood platelets. J Vet Pharmacol Ther 1994;17:374-378.

  67. Cambridge H, Lees P, Hooke RE, Russell CS. Antithrombotic actions of aspirin in the horse. Equine Vet J 1991;23:123-127.

  68. Jarvis GE, Evans RJ.Endotoxin induced platelet aggregation in heparinised equine whole blood in vitro. Res Vet Sci 1994;57:317-324.

  69. Hagedorn HW, Bock M, Schulz R. Acetylsalicylic acid and blood coagulation in horses. Dt tierarztl Wschr 1992;99:410-412.

  70. Auer DE, Ng JC, Seawright AA. Copper salicylate and copper phenylbutazone as topically applied anti-inflammatory agents in the rat and horse. J Vet Pharmacol Ther 1990;13:67-75.

  71. Johansson IM, Kallings P, Hammarlund-Udenaes M. Studies of meclofenamic acid and two metabolites in horses pharmacokinetics and effects on exercise tolerance. J Vet Pharmacol Ther 1991; 14:235-242.

  72. Johnson CB, Taylor PM, Brearley JC, Young SS. Comparison of phenylbutazone, flunixin and carprofen for the provision of post-operative analgesia in equine surgery. J Vet Anaesth 1993;20:38-39.

  73. Johnson CB, Taylor PM, Young SS, Brearley JC. Postoperative analgesia using phenylbutazone, flunixin or carprofen in horses. Vet Rec 1993;133:336-338.

  74. Schatzmann U, Gugelmann M, Von Cranach J, Ludwig BM, Rehm WF. Pharmacodynamic evaluation of the peripheral pain inhibition by carprofen and flunixin in the horse. Schweizer Arch Tierheilk 1990;132:497-504.

  75. McKellar QA, Bogan JA, Von Fellenberg RL, Ludwig B, Cawley GD. Pharmacokinetic, biochemical and tolerance studies on carprofen in the horse. Equine Vet J 1991;23:280-284.

  76. Carpenter SL, McDonnell WM. Misuse of veterinary phenylbutazone. Arch Inter Med 1995;155:1229-1231.

  77. Read WK. Renal medullary crest necrosis associated with phenylbutazone therapy in horses. Vet Pathol 1983;20:662-669.

  78. Toutain PL, Autefage A, Legrand C, Alvinerie M. Plasma concentrations and therapeutic efficacy of phenylbutazone and flunixin meglumine in the horse: Pharmacokinetic/pharmacodynamic modelling. J Vet Pharmacol Ther 1994;17:459-469.

  79. Sime DM, Engen RL, Miller-Graber P. Frequency and use of medications in horses racing at Prairie Meadows. Iowa St Univ Vet 1994;56:15-18.

  80. Skarra TK. Forgiftning med fynylbutazon hos hest. Norsk Vet Tidsskr 1994;106:443-449.

  81. Trailovic D, Litricin V, Trailovic R, Petrujkic T, Krstic V. Osvrt na neke stetne efekte fenilbutazona u sportskih konja. Vet Glasn 1989;43:635-639.

  82. Meschter CL, Cummings JF, Krook L, Maylin GA. Phenylbutazone-induced microvascular lesions in the gastric mucosa of horses. Toxicol Pathol 1987;15:371-372,

  83. Meschter CL, Gilbert M, Krook L. Maylin G, Corradino R. The effects of phenylbutazone on the morphology and prostaglandin concentrations of the pyloric mucosa of the equine stomach. Vet Pathol 1990;27:244-253.

  84. Meschter CL, Krook L, Maylin GA. Phenylbutazone induced microvascular lesions in the gastrointestinal mucosa of horses. Equine Vet J 1989;7(Suppl.): 141.

  85. Meschter CL, Gilbert M, Krook L, Maylin G, Corradino R. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study. Equine Vet J 1990;22:255-263.

  86. McDonnell SM, Love CC, Pozor MA, Diehl NK. Phenylbutazone treatment in breeding stallions: preliminary evidence for no effect on semen or testicular size. Theriogenology 1992;37: 1225-1232.

  87. Crisman MV, Sams RA, Irby MH. The disposition of phenylbutazone in lactating mares and its effect on nursing foals. Proceedings of the 36th Annual Convention of the American Association of Equine Practitioners; 1990 December 2-5; Lexington (Kentucky) U.S.A. Lexington (Kentucky): American Association of Equine Practitioners, 1990: 127-131.

  88. Crisman MV, Wilcke JR, Sams RA, Gerken DF. Concentrations of phenylbutazone and oxyfenbutazone in post-parturient mares and their neonatal foals. J Vet Pharmacol Ther 1991;14:330-334.

  89. Zicker SC, Brumbaugh GW. Effects of phenylbutazone on glucose tolerance and on secretion of insulin in healthy geldings. Am J Vet Res 1989;50:743-746.

  90. Geor RJ, Petrie L, Papich MG, Rousseaux C. The protective effects of sucralfate and ranitidine in foals experimentally intoxicated with phenylbutazone. Can J Vet Res 1989;53:231-238.

  91. Wilson DV, Eberhart SW, Robinson NE, Rice R, Gray PR. Cardiovascular responses to exogenous platelet-activating factor (PAF) in anesthetized ponies, and the effects of a PAF antagonist, WEB 2086. Am J Vet Res 1993;54:274-279.

  92. Quintavalla F, Bianchini L, De Haas V, Katz T. Clinical experience with the treatment of horses with flunixin meglumine oral paste. Ippologia 1993;4:41-47.

  93. Helmy MM, Soliman FA, Ragab AM, Aggag BI. Effects of flunixin meglumine (Finadyne) on blood of horses in the treatment of some common inflammatory conditions. Egypt J comp Pathol Clin Pathol 1991;4:113-133.

  94. Held JP, Daniel GB. Use of nonimaging nuclear medicine techniques to assess the effect of flunixin meglumine on effective renal plasma flow and effective renal blood flow in healthy horses. Am J Vet Res 1991;52:1619-1621.

  95. Carrick JB, Papich MG, Middleton DM. Effets cliniques et anatomopathologiques de la flunixine meglumine dans le traitment de poulains nouveaunés. Action Vét 1991; 7:(Suppl. 1186):10-12.

  96. Carrick JB, Papich MG, Middleton DM, Naylor JM, Town-send HGG. Clinical and pathological effects of flunixin meglumine administration to neonatal foals. Can J Vet Res 1989;53:195-201.

  97. Traub-Dargatz JL, Bertone JJ, Gould DH, Wrigley RH, Weiser MG, Forney SD. Chronic flunixin meglumine therapy in foals. Am J Vet Res 1988;49:7-12.

  98. Gill KK, Kroeger EA. Effects of indomethacin on neural and myogenic components of equine airway smooth muscle. J Pharmacol Exp Ther 1990;252:358-364.

  99. Vandenbossche GMR, Bouckaert S, De Muynck C, Remon JP, Mommens G. Side effects of indomethacin in ponies. Vet Rec 1990;127:316.

  100. 100.Owens JG, Kamerling SG, Stanton SR, Keowen ML. Effects of ketoprofen and phenylbutazone on chronic hoof pain and lameness in the horse. Equine Vet J 1995;27:296-300.

  101. Jackman BR, Moore JN, Barton MH, Morris DD. Comparison of the effects of ketoprofen and flunixin meglumine on the in vitro response of equine peripheral blood monocytes to bacterial endotoxin. Can J Vet Res 1994;58:138-143.

  102. Longo F, Autefage A, Bayle R, Van Gool F. Efficacité du kétoprofene dans les affections musculo squelettiques du cheval. Bull Mens Soc Vét Prat Fr 1990;74:349-364,366-367.

  103. Betley M, Sutherland SF, Gregoricka M, Pollet RA. The analgesic effect of ketoprofen for use in treating equine colic as compared to flunixin meglumine. Equine Pract 1991;13:11-16.

  104. Longo F, Autefage A, Bayle R, Keister M, Van Gool, F. Efficacité du kétoprofene dans le traitement des coliques chez le cheval. Bull mens Soc vét prat Fr 1990;74:377-394.

  105. Gregoricka MJ, Sutherland SF, Dedrickson BJ, Busch KR. Assessment of the intramuscular administration of ketoprofen. Equine Pract 1990;12:15-22.

  106. McDowell M, Wickler SJ. Effect of naproxen on bleeding time in the horse. J Equine Vet Sci 1990;10:162-163.

  107. Sumano HL, De Vizcaya A, Brumbaugh GW. Tolerance and clinical evaluation of piroxicam in dogs. Canine Pract 1996;21:16-19.




2020     |     www.medigraphic.com